Ad
related to: Moderna COVID-19 Vaccine (Spikevax)
Search results
Moderna’s sales from its only product, the COVID-19 vaccine, fell 91% from last year
Fortune via Yahoo Finance· 20 hours agoIn the first quarter of the year, Moderna reported $167 million in sales of its only product on the...
Moderna Reports Smaller Than Expected Q1 Loss, Prepares For RSV Vaccine And Spikevax 2024-2025...
Benzinga via Yahoo Finance· 22 hours agoThursday, Moderna Inc (NASDAQ:MRNA) reported a first-quarter EPS loss of $(3.07), down from an...
Moderna COVID vaccine sales plummet 91 percent - The Boston Globe
The Boston Globe· 1 day agoSales of Moderna’s COVID-19 vaccine plunged 91 percent from the previous year for the first quarter...
Moderna stock surges 15% after it beat earnings expectations despite plummeting COVID vaccine sales
Quartz· 1 day agoModerna stock soared on Thursday after its first-quarter earnings report sailed past Wall Street’s...
Moderna posts quarterly sales beat, smaller loss than expected
Reuters via Yahoo Finance· 1 day ago(Reuters) -Moderna on Thursday reported quarterly revenue that beat Wall Street estimates but came...
Moderna expects CDC to view its RSV vaccine as equal to rival shots
Reuters· 1 day ago, opens new tab said on Thursday it expects U.S. Center for Disease Control and Prevention (CDC)...
Why Moderna Stock Blasted 13% Higher Today
Motley Fool via Yahoo Finance· 19 hours agoModerna (NASDAQ: MRNA) was a fine stock to heal an ailing portfolio on the second-to-last trading day of the week. The company, which developed and sells...
Moderna reports $1.2bn net loss in Q1 2024
Pharmaceutical Technology via Yahoo Finance· 9 hours agoThis downturn aligns with the expected transition to a seasonal market for Covid-19 vaccines. During Q1 2023, Moderna
Moderna Inc (MRNA) Q1 2024 Earnings: Significant Revenue Decline
Guru Focus· 1 day agoOn May 2, 2024, Moderna Inc (MRNA, Financial) released its 8-K filing, disclosing a challenging first quarter with total revenues of $167 million, a stark decline from $1.9 ...
Is Moderna Stock A Buy On Its Eye-Popping First-Quarter Sales Beat?
Investor's Business Daily· 1 day agoModerna is rivaling vaccine makers Pfizer and Novavax. Still, the market for Covid boosters is...
